Reporting of Adjuvant Breast Cancer Trials: When Is the Right Time?
- 1 January 2012
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (1), 1-2
- https://doi.org/10.1200/jco.2011.38.2747
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX TrialJournal of Clinical Oncology, 2012
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 StudiesPLoS Medicine, 2010
- Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).Journal of Clinical Oncology, 2010
- Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialThe Lancet Oncology, 2009
- Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast CancerNew England Journal of Medicine, 2006
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJAMA, 2006
- Cautionary tales of survival analysis: conflicting analyses from a clinical trial in breast cancerBritish Journal of Cancer, 1997